Back to top

LACOG 0223 / GOG-3073 – ROSELLA

  /    /  LACOG 0223 / GOG-3073 – ROSELLA

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian Primary Peritoneal, or Fallopian-Tube Cancer

Type of Study: Clinical Trial

Sponsor / Support: Corcept Therapeutics, GOG, LACOG and EVA – Grupo Brasileiro de Tumores Ginecológicos

Primary Objectives: To evaluate progression-free survival (PFS) by BICR in patients treated with intermittent regimen of relacorilant in combination nab-paclitaxel compared with patients trated with nab-paclitaxel monotherapy.

Design: This is a Phase 3, randomized, two-arm, open-label study

Sample Size: 360 patients (52 – Brazil)

Principal Investigator:  Mariana Scaranti

Countries LATAM: Brazil

Clinicaltrials.gov IdentifierNCT05257408

The study is open to patients participation in the following research sites:

Oncocentro Ceará / Fortaleza / CE / Brazil

OncoStar Rede D'or / Brasília / DF / Brazil

Hospital Alemão Oswaldo Cruz / São Paulo / SP / Brazil

Clínica AMO - Assistência Multidisciplinar em Oncologia / Salvador / BA / Brazil

Liga Norte Riograndense Contra o Câncer / Natal / RN / Brazil

Hospital Nove de Julho / São Paulo / SP / Brazil

Hospital Moinhos de Vento / Porto Alegre / RS / Brazil

A.C Camargo Cancer Center / São Paulo / SP / Brazil